214 related articles for article (PubMed ID: 19855097)
41. Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy.
Chaudhary N; Kabra M; Gulati S; Gupta YK; Pandey RM; Bhatia BD
BMC Pediatr; 2016 May; 16():66. PubMed ID: 27179628
[TBL] [Abstract][Full Text] [Related]
42. Distribution of CYP2C9*13 allele in the Chinese Han and the long-range haplotype containing CYP2C9*13 and CYP2C19*2.
Si D; Wang J; Zhang Y; Zhong D; Zhou H
Biopharm Drug Dispos; 2012 Sep; 33(6):342-5. PubMed ID: 22886551
[TBL] [Abstract][Full Text] [Related]
43. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
[TBL] [Abstract][Full Text] [Related]
44. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
Odani A; Hashimoto Y; Otsuki Y; Uwai Y; Hattori H; Furusho K; Inui K
Clin Pharmacol Ther; 1997 Sep; 62(3):287-92. PubMed ID: 9333104
[TBL] [Abstract][Full Text] [Related]
45. Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies.
Shintani M; Ieiri I; Inoue K; Mamiya K; Ninomiya H; Tashiro N; Higuchi S; Otsubo K
Clin Pharmacol Ther; 2001 Aug; 70(2):175-82. PubMed ID: 11503012
[TBL] [Abstract][Full Text] [Related]
46. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19.
Donahue SR; Flockhart DA; Abernethy DR; Ko JW
Clin Pharmacol Ther; 1997 Nov; 62(5):572-7. PubMed ID: 9390115
[TBL] [Abstract][Full Text] [Related]
47. CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects.
Soga Y; Nishimura F; Ohtsuka Y; Araki H; Iwamoto Y; Naruishi H; Shiomi N; Kobayashi Y; Takashiba S; Shimizu K; Gomita Y; Oka E
Life Sci; 2004 Jan; 74(7):827-34. PubMed ID: 14659971
[TBL] [Abstract][Full Text] [Related]
48. Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy.
Lin CJ; Yen MF; Hu OY; Lin MS; Hsiong CH; Hung CC; Liou HH
Pharmacotherapy; 2008 Jan; 28(1):35-41. PubMed ID: 18154472
[TBL] [Abstract][Full Text] [Related]
49. Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.
Shon JH; Yoon YR; Kim MJ; Kim KA; Lim YC; Liu KH; Shin DH; Lee CH; Cha IJ; Shin JG
Br J Clin Pharmacol; 2005 May; 59(5):552-63. PubMed ID: 15842554
[TBL] [Abstract][Full Text] [Related]
50. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose.
Zhao F; Loke C; Rankin SC; Guo JY; Lee HS; Wu TS; Tan T; Liu TC; Lu WL; Lim YT; Zhang Q; Goh BC; Lee SC
Clin Pharmacol Ther; 2004 Sep; 76(3):210-9. PubMed ID: 15371982
[TBL] [Abstract][Full Text] [Related]
51. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor.
Chen Y; Ferguson SS; Negishi M; Goldstein JA
J Pharmacol Exp Ther; 2004 Feb; 308(2):495-501. PubMed ID: 14600250
[TBL] [Abstract][Full Text] [Related]
52. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
[TBL] [Abstract][Full Text] [Related]
53. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
[TBL] [Abstract][Full Text] [Related]
54. Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations.
Pedersen RS; Brasch-Andersen C; Sim SC; Bergmann TK; Halling J; Petersen MS; Weihe P; Edvardsen H; Kristensen VN; Brøsen K; Ingelman-Sundberg M
Eur J Clin Pharmacol; 2010 Dec; 66(12):1199-205. PubMed ID: 20665013
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.
Kidd RS; Straughn AB; Meyer MC; Blaisdell J; Goldstein JA; Dalton JT
Pharmacogenetics; 1999 Feb; 9(1):71-80. PubMed ID: 10208645
[TBL] [Abstract][Full Text] [Related]
56. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.
Loebstein R; Vecsler M; Kurnik D; Austerweil N; Gak E; Halkin H; Almog S
Clin Pharmacol Ther; 2005 May; 77(5):365-72. PubMed ID: 15900282
[TBL] [Abstract][Full Text] [Related]
57. Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients.
Mushiroda T; Ohnishi Y; Saito S; Takahashi A; Kikuchi Y; Saito S; Shimomura H; Wanibuchi Y; Suzuki T; Kamatani N; Nakamura Y
J Hum Genet; 2006; 51(3):249-253. PubMed ID: 16432637
[TBL] [Abstract][Full Text] [Related]
58. Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region.
Dagenais R; Wilby KJ; Elewa H; Ensom MHH
Drugs R D; 2017 Sep; 17(3):341-361. PubMed ID: 28748348
[TBL] [Abstract][Full Text] [Related]
59. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
[TBL] [Abstract][Full Text] [Related]
60. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI).
Pachkoria K; Lucena MI; Ruiz-Cabello F; Crespo E; Cabello MR; Andrade RJ;
Br J Pharmacol; 2007 Mar; 150(6):808-15. PubMed ID: 17279092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
